OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) Presents Interesting Picture as a Bite-Size Buyout Candidate

OncBioMune Pharmaceuticals Inc (OTCMKTS:OBMP) is in an interesting phase of its existence. The company just solidified its sense of credibility in the space with a recent announcement of a productive meeting with top staffing scientists at the host hospital of the Company’s upcoming Phase 2 trial of ProscaVax for prostate cancer. That represents the first […]

Plandai Biotechnology Inc (OTCMKTS:PLPL) And Generex Biotechnology Corporation (OTCMKTS:GNBT) Issues Promising PRs

Plandai Biotechnology Inc (OTCMKTS:PLPL) and Generex Biotechnology Corporation (OTCMKTS:GNBT) are the two OTC traded stocks that have been the center of attraction after they issued promising PRs. Plandai reported an amendment to its preciously finalized deal with USN Worldwide. Under the new amended deal with USN, it will now expand its Phytofare® sales to USN […]

Impact Of Billion Dollar Deal Between Celgene Corporation (NASDAQ:CELG) And Juno Therapeutics Inc (NASDAQ:JUNO) On Biotech Market

Celgene Corporation (NASDAQ:CELG) announced yesterday that it will spend roughly $1 billion to venture into a partnership with Juno Therapeutics Inc (NASDAQ:JUNO). The two firms will engage in a ten-year partnership that is expected to keep the biotech bull market going. Celgene maintains that the deal is in the best interest of the company, regardless […]

Celgene Corporation (NASDAQ:CELG) Gets FDA Fast Track Designation For Two Trials

Celgene Corporation (NASDAQ:CELG) collaborations have been benefiting the company, and the U.S. Food and Drug Administration has given a green signal to two of its projects. Reportedly, the drug deals with Agios Pharmaceuticals Inc (NASDAQ:AGIO) and Acceleron Pharma Inc (NASDAQ:XLRN) are set to reach their final trials after the regulatory nod. The FDA has added […]

Nantworks Acquires Sorrento Therapeutics Inc (NASDAQ:SRNE) Subsidiary For $90 Million

NantWorks has acquired Igdrasol, a wholly-owned subsidiary of Sorrento Therapeutics Inc (NASDAQ:SRNE) for $90 million. The deal is part of the company’s plans for achieving a breakthrough in the cancer treatment domain. Igdrasol is underway a Phase 3 trial for cancer treatment through the Cynviloq drug. As an alternative to the cancer treatment drug Abraxane […]

Celgene Corporation (NASDAQ:CELG) R&D Speedy Deals Pay Off

Celgene Corporation (NASDAQ:CELG) is reaping the fruits of its speedy efforts in which the company made quite a number of lucrative deals and transactions. The company is now enjoying some good times though it has not been smooth sailing in the past. It has been a treacherous road full of uncertainties as well as irregular […]

Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals Inc (NASDAQ:AGIO) Tie Up for the Third Time

Celgene Corporation (NASDAQ:CELG) is deepening its ties with biotech company Agios Pharmaceuticals Inc (NASDAQ:AGIO) with a 50-50 collaboration on another preclinical cancer candidate. Celgene will give $10 million up front and promises up to $70 million more to get a share of AG-881. AG-881 is Agios’ therapy that aims to target cancer metabolism with the […]

Celgene Corporation (NASDAQ:CELG) to buy Cancer research Company Quanticel Pharmaceuticals

Celgene Corporation (NASDAQ:CELG) is buying up Quanticel Pharmaceuticals for a deal worth $485 million. The deal comes after Clegene teamed up with Versant Ventures to help Quanticel get off the ground Quanticel is a cancer focused biotech and has a drug recover engine that uses single cell genomic analysis to decode cancer cells and highlight […]

Celgene Corporation (NASDAQ:CELG) Could Turn Things Upside Down For Psoriasis Drug Competitors

Boston, MA 09/24/2014 (wallstreetpr) – Celgene Corporation (NASDAQ:CELG) could upset companies like AbbVie Inc (NYSE:ABBV), Amgen, Inc. (NASDAQ:AMGN) and Pfizer Inc. (NYSE:PFE), which are currently minting hefty money through their psoriasis injections currently selling in the market. Celgene Corporation (NASDAQ:CELG) reported on Tuesday that it has received the approval from the Food and Drug Administration for […]

Senior unsecured Notes Of Celgene Corporation (NASDAQ:CELG) Priced At $2.5 Billion

Boston, MA 05/08/2014 (wallstreetpr) –  The aggregate principal prices of three unsecured senior notes were announced by Celgene Corporation (NASDAQ:CELG) today. The company has priced these at $2.5 billion. Of these three notes in question, $500 million will mature in 2019 bearing an annual interest of 2.25%. Another worth $1000 million will mature in 2024 […]

Celgene Corporation (NASDAQ:CELG): The Pharma Giant With a Cutting Edge

Boston, MA 04/28/2014 (wallstreetpr) – Celgene Corporation (NASDAQ:CELG) has reported a greater than expected Q1 profit on account of higher sales of its oncology products, especially Reylimid, its flagship multiple myeloma drug. The profit margin, however, dropped significantly due to greater expenditure involved in launching new drugs, as well as greater costs incurred in research and […]

Mylan Inc (NASDAQ:MYL) Makes Acquisition Contact With Swedish Rival Meda, Sues Celgene Corporation (NASDAQ:CELG)

Boston, MA 04/04/2014 (wallstreetpr) – Mylan Inc (NASDAQ:MYL) is said to be considering a bid to acquire Meda, a Swedish competitor, people familiar with the matter said today. The company has reportedly made preliminary discussions about merger, yet details of the talks are yet to be made public. Discussions about merger deal between Mylan and Meda […]

Early Investors In Acceleron Pharma Inc (NASDAQ:XLRN) Selling Shares, But Who’s On The Receiving End?

Boston, MA 04/02/2014 (wallstreetpr) – Investors who acquired stake in Acceleron Pharma Inc (NASDAQ:XLRN) before its IPO have agreed to sell their stake to a major drugmaker that is seeking to up its stake in the company. The early investors to cash in on their holding, through sale to Celgene Corporation (NASDAQ:CELG), include Flagship Ventures, Venrock, […]

Celgene Corporation (NASDAQ:CELG) shares surged by 7.87%

Boston, MA 07/12/2013 (wallstreetpr) – In the recently announced results for the Phase III studies of REVLIMID which was tested in combination with dexamethasone, it was reported that the primary endpoint was effectively reached. The test was conducted on patients who were recently diagnosed with multiple myeloma. The Phase III studies have resulted in the primary […]